Literature DB >> 21606953

Increased IL-1β activation, the culprit not only for defective insulin secretion but also for insulin resistance?

Marianne Böni-Schnetzler1, Marc Y Donath.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21606953      PMCID： PMC3193499          DOI： 10.1038/cr.2011.85

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


× No keyword cloud information.
  15 in total

Review 1.  Type 2 diabetes as an inflammatory disease.

Authors:  Marc Y Donath; Steven E Shoelson
Journal:  Nat Rev Immunol       Date:  2011-01-14       Impact factor: 53.106

2.  IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat.

Authors:  J A Ehses; G Lacraz; M-H Giroix; F Schmidlin; J Coulaud; N Kassis; J-C Irminger; M Kergoat; B Portha; F Homo-Delarche; M Y Donath
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-30       Impact factor: 11.205

3.  The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity.

Authors:  Rinke Stienstra; Leo A B Joosten; Tim Koenen; Berry van Tits; Janna A van Diepen; Sjoerd A A van den Berg; Patrick C N Rensen; Peter J Voshol; Giamilla Fantuzzi; Anneke Hijmans; Sander Kersten; Michael Müller; Wim B van den Berg; Nico van Rooijen; Martin Wabitsch; Bart-Jan Kullberg; Jos W M van der Meer; Thirumala Kanneganti; Cees J Tack; Mihai G Netea
Journal:  Cell Metab       Date:  2010-12-01       Impact factor: 27.287

4.  Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study.

Authors:  Edwin J P van Asseldonk; Rinke Stienstra; Tim B Koenen; Leo A B Joosten; Mihai G Netea; Cees J Tack
Journal:  J Clin Endocrinol Metab       Date:  2011-04-20       Impact factor: 5.958

5.  Increased number of islet-associated macrophages in type 2 diabetes.

Authors:  Jan A Ehses; Aurel Perren; Elisabeth Eppler; Pascale Ribaux; John A Pospisilik; Ranit Maor-Cahn; Xavier Gueripel; Helga Ellingsgaard; Marten K J Schneider; Gregoire Biollaz; Adriano Fontana; Manfred Reinecke; Francoise Homo-Delarche; Marc Y Donath
Journal:  Diabetes       Date:  2007-06-19       Impact factor: 9.461

6.  Metabolic endotoxemia initiates obesity and insulin resistance.

Authors:  Patrice D Cani; Jacques Amar; Miguel Angel Iglesias; Marjorie Poggi; Claude Knauf; Delphine Bastelica; Audrey M Neyrinck; Francesca Fava; Kieran M Tuohy; Chantal Chabo; Aurélie Waget; Evelyne Delmée; Béatrice Cousin; Thierry Sulpice; Bernard Chamontin; Jean Ferrières; Jean-François Tanti; Glenn R Gibson; Louis Casteilla; Nathalie M Delzenne; Marie Christine Alessi; Rémy Burcelin
Journal:  Diabetes       Date:  2007-04-24       Impact factor: 9.461

7.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.

Authors:  Haiyan Xu; Glenn T Barnes; Qing Yang; Guo Tan; Daseng Yang; Chieh J Chou; Jason Sole; Andrew Nichols; Jeffrey S Ross; Louis A Tartaglia; Hong Chen
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

8.  Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I.

Authors:  Marianne Böni-Schnetzler; Simone Boller; Sarah Debray; Karim Bouzakri; Daniel T Meier; Richard Prazak; Julie Kerr-Conte; Francois Pattou; Jan A Ehses; Frans C Schuit; Marc Y Donath
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

9.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

Authors:  Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Aage Vølund; Jan A Ehses; Burkhardt Seifert; Thomas Mandrup-Poulsen; Marc Y Donath
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

10.  The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.

Authors:  Fabio Martinon; Kimberly Burns; Jürg Tschopp
Journal:  Mol Cell       Date:  2002-08       Impact factor: 17.970
View more
  7 in total

Review 1.  How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes.

Authors:  Marianne Böni-Schnetzler; Marc Y Donath
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

2.  IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies.

Authors:  Aimalie L Hardaway; Izabela Podgorski
Journal:  Future Med Chem       Date:  2013-06       Impact factor: 3.808

3.  Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase.

Authors:  Liqi Tong; G Aleph Prieto; Enikö A Kramár; Erica D Smith; David H Cribbs; Gary Lynch; Carl W Cotman
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

4.  Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms.

Authors:  R Palmér; E Nyman; M Penney; A Marley; G Cedersund; B Agoram
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-06-11

5.  Effects of Two Different Dietary Patterns on Inflammatory Markers, Advanced Glycation End Products and Lipids in Subjects without Type 2 Diabetes: A Randomised Crossover Study.

Authors:  Yoona Kim; Jennifer B Keogh; Peter M Clifton
Journal:  Nutrients       Date:  2017-03-29       Impact factor: 5.717

6.  Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance.

Authors:  Wen-Jun Su; Wei Peng; Hong Gong; Yun-Zi Liu; Yi Zhang; Yong-Jie Lian; Zhi-Yong Cao; Ran Wu; Lin-Lin Liu; Bo Wang; Yun-Xia Wang; Chun-Lei Jiang
Journal:  J Neuroinflammation       Date:  2017-10-30       Impact factor: 8.322

7.  Peroxisome Proliferator-Activated Receptor-Gamma Reduces ER Stress and Inflammation via Targeting NGBR Expression.

Authors:  Jialing Ma; Peng Zeng; Lipei Liu; Mengmeng Zhu; Juan Zheng; Chengyi Wang; Xiaokang Zhao; Wenquan Hu; Xiaoxiao Yang; Yajun Duan; Jihong Han; Qing R Miao; Yuanli Chen
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.